OR WAIT null SECS
Model N positions itself for coming revisions in pharma trade practices
Model N made its bones with the concept of revenue management: in life sciences, analyzing the elements of commercial contracts to maximize profitability and minimizing poorly executed incentive or rebate programs. Now, in a commissioned 2019 survey across its prospect base of life sciences and high tech companies, Model N finds that the top concerns for financial well-being are:
Especially in the current era of intense questioning of the life sciences practices in working with PBMs and other intermediaries, revenue leakage is a key priority. “It makes perfect sense why this is so important,” says Jason Blessing, Model N CEO. “Revenue leakage, often from incentive overpayments, reduces top line revenue and negatively impacts margins.”
The survey, announced at the company’s annual Rainmaker Conference (Miami Beach, March 11-13), has recommendations based on what top-performing companies are doing to maximize revenue and minimize leakage and compliance problems:
The full survey is available for download at Model N's website.